Utah Medical Products share price today

Utah Medical Products, Inc.'s share price was $72.42 at the close on 4 November 2026. That is 6.2% above its average price over the last 200 trading days. In the last 52 weeks it traded between $55 and $75, and at that close it sat 89% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). The phase helps read everything below.

Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 1 week in a row.

Over the last 1 year the share price moved +28% while the S&P 500 moved +23%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Utah Medical Products, Inc. paid $1.24 per share over the last four reported quarters. The most recent declaration was $0.31 for Jun 2026. At today's price of $72.42 that is a yield of 1.71%, based on dividends already paid, not a forecast.

A dividend is cash paid out for each share. The 12-month total is the four most recent quarters added together.

Utah Medical Products is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

Utah Medical Products, Inc. earned $2.8 M of net profit in the Sep 2026 quarter, +5.9% on the same quarter a year earlier. Full-year FY25 profit was $11.3 M. Over 4 years profit has grown −6.5% a year on average. That is 32.3% of the quarter's revenue. The same quarter a year earlier earned $2.6 M.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY25 profit was $11.3 M (−18.7% on the year before).

Why profit moved: revenue changed −12.1% on a year earlier and the margin moved +4.2 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed −8.0% and revenue −9.4%. Profit and revenue are moving at about the same pace.

Utah Medical Products, Inc. reported $8.6 M of revenue in the Sep 2026 quarter, −12.1% on the same quarter a year earlier. Over 4 years it has grown −5.9% a year on average. The last full year, FY25, came in at $38.5 M. The last four reported quarters add to $34.9 M.

Revenue is everything the company billed its customers in the period.

FY25 revenue was $38.5 M, −5.8% on the year before.

Recent pace: the last four quarters grew −9.4% on average, against −5.9% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew −9.6%, against −11.0% a year over the last 8 quarters (stabilising); profit over the last 12 months grew −8.4%, against −16.5% a year (accelerating).

Utah Medical Products, Inc.'s operating margin was 34.8% in the Sep 2026 quarter, 4.2 percentage points higher than the same quarter a year ago. Across 5 years it has been between 33.1% and 38.5%. The latest quarter is within that range.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +4.2 percentage points on the year while gross margin changed −1.0 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 124% of Utah Medical Products, Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $14.7 M of operating cash against $11.3 M of profit. After $371 K of spending on assets, $14.3 M was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

Utah Medical Products, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $1.2 M on assets over the last 3 years. Averaged over those years that is 1.1% of FY25 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $1.2 M over the last 3 years.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Utah Medical Products, Inc.'s P/E is 21.7×, near the high end of its own history: higher than 84% of past readings. Its usual P/E (the middle reading) is 18.6×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

Why the multiple is where it is: over the past year earnings per share moved −12.1% while the price moved +26.2%. The price did better than earnings, which pushed the multiple up within its own range.

In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.

Utah Medical Products, Inc.'s business is getting worse. Revenue, profit and EPS growth are shrinking: revenue growth is −9.6% in the latest quarter, against −3.9% at its best in 12 quarters, with ROCE steady at 9.9%. This is based on 12 quarters of 4 measures.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Utah Medical Products, Inc. earned a ROE of 10% in FY25. Its return on capital used (ROIC) is 20.5 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 29.3% net margin and 0.31× asset turnover (sales divided by assets).

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

Why the return is what it is (FY25): a 29.3% net margin × 0.31× asset turnover × 1.03× leverage (assets divided by equity) ≈ 9.4% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: 26.9% − 6.4% = +20.5 percentage points. The 6.4% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value.

The 26.9% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 29.8%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

Utah Medical Products, Inc. has total debt of $180 K against shareholder equity of $123 M as of Sep 2026, so its debt is 0.00× its equity, which is very little. Year by year, that ratio went from 0.00 in FY21 to 0.00 in FY25. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

5.1% of Utah Medical Products, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 3.8 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

It is a single reading at one point in time; we do not have its history.

Why it is at this level: the figure does not say who has the short positions or why, so we show the level without guessing the story.

For Utah Medical Products, Inc., the Z-score is 49.60. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

Why it matters: a Z-score of 49.60 is well clear of the danger zone, so the balance sheet is not the risk here.

There is no score against its industry: Utah Medical Products, Inc. is not among the largest members shown in this industry comparison for Medical Instruments & Supplies.

The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown.

No sector comparison is shown here, not among the largest members shown in this industry comparison.

Utah Medical Products is the 36th largest of 38 Medical Instruments & Supplies companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: AngioDynamics, Inc., Embecta Corp., Sanara MedTech Inc. and OraSure Technologies, Inc. Just below it: Pro-Dex, Inc. and Anbio Biotechnology.

Medical Instruments & Supplies companies close in size

32. AngioDynamics, Inc. $515 million
33. Embecta Corp. $369 million
34. Sanara MedTech Inc. $297 million
35. OraSure Technologies, Inc. $257 million
36. Utah Medical Products, Inc. $230 million
37. Pro-Dex, Inc. $203 million
38. Anbio Biotechnology $162 million

All 38 Medical Instruments & Supplies companies, largest first

Companies close in size in other industries

3322. SIGA Technologies, Inc. $223 million · Drug Manufacturers - Specialty & Generic
3323. Chicago Atlantic Real Estate Finance, Inc. $222 million · REIT - Mortgage
3324. Utah Medical Products, Inc. $222 million
3325. Biodesix, Inc. $222 million · Diagnostics & Research
3326. Electromed, Inc. $221 million · Medical Devices

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.